CRH Medical Corporation (CRH) focuses on providing physicians throughout the United States with innovative products and services for the treatment of gastrointestinal (GI) diseases in North America.
The CRH O’Regan System is a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. The company distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly...
CRH Medical Corporation (CRH) focuses on providing physicians throughout the United States with innovative products and services for the treatment of gastrointestinal (GI) diseases in North America.
The CRH O’Regan System is a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. The company distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists (GIs) it serves. The CRH O’Regan System is used in all 48 lower U.S. states.
The company owns Gastroenterology Anesthesia Associates, LLC (GAA), a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures. As of December 31, 2020, the company had a majority ownership interest in 32 GI anesthesia practices in 13 U.S. states and serviced approximately 450,000 patient cases annually.
The CRH O’Regan System
The ligator is a plastic plunger suction device resembling a syringe, with a built-in obturator to ease insertion, which allows for a band to be applied to a given hemorrhoid. This procedure can be performed under direct visualization with a specially designed anoscope or using a ‘touch’ technique where the device is inserted up to a mark through the anus and directed to one of the hemorrhoid cushions, which is then banded.
The company is introducing the CRH O’Regan System into the curriculum of the approximately 190 academic and hospital-based Gastroenterology Fellowship Programs throughout the United States as perianal care is not traditionally a topic covered during training.
The treatment of hemorrhoids is a natural extension of the GI practice. Hemorrhoid treatment with the CRH O’Regan System expands the continuum of care and provides a fast and painless solution to patients. Since many hemorrhoid patients also require colonoscopy and other endoscopic services, adoption of the CRH O’Regan System creates additional patient and procedural revenue for the GIs’ traditional practice.
The company provides a comprehensive support program for GI practices, including providing clinical training, operational training and marketing programs and materials.
The company provides physician-to-physician training for GIs at their own practice setting with patients they identify and recruit for treatment. This enables the GI to see a variety of pathologies and learn the procedure by treating patients in a ‘hands-on’ manner, leading to a greater comfort level with the technology and the associated necessary treatment protocols. These initial patients are also then scheduled for subsequent bandings, contributing to the start-up and growth of hemorrhoid procedures within the practice.
The company also provides operational training and support to ensure that GI office staff are comfortable describing the procedure and are able to address the questions most frequently asked by hemorrhoid sufferers seeking its treatment. The training includes hemorrhoid education, technology facts, phone scripts, frequently-asked questions, optimal patient flow processes and scheduling methodologies; and a billing and coding overview. In addition, the company provides hemorrhoid content that may be added to the GI practice website.
The company provides a comprehensive marketing support program to assist GIs with integrating the CRH O’Regan System into their practice. Marketing programs and materials are available at no charge and are designed to educate new and existing patients about the procedure.
The company also provides web-based marketing resources to GI practices by adding their practice profile to the CRH website. The CRH consumer website (www.crhsystem.com) directs hemorrhoid sufferers to trained physicians near them who offer its procedure.
Regulatory Approval
The company has FDA 510(k) clearance (K963166 and K020702) for the United States and Medical Device License #65043 for Health Canada. These registrations are legal prerequisites for the company to market and sell the CRH O’Regan Ligator, Anoscope and CRH O’Regan System in the United States and Canada, and many countries worldwide that accept these registrations. The company sub-contracts the design and manufacture of its O’Regan products to a Canadian manufacturer that holds certification for CRH products to ISO13485:2016 MDSAP.
The company manages sub-contracted activities and Quality Management System activities to ensure compliance with the requirements of ISO 13485:2016 MDSAP and Current Good Manufacturing Practice, and is committed to continuously improve the quality of its products and services to better satisfy the needs and expectations of its customers.
Intellectual Property
As of December 31, 2020, the company’s patent portfolio consisted of 9 issued U.S. and foreign patents and 4 pending U.S. and foreign patent applications. Of these, its issued patents expire between approximately 2021 and 2034. In addition, the company has 3 U.S. and foreign trademark registrations.
Gastroenterology Anesthesia Services
The company provides anesthesia services for patients undergoing endoscopic procedures performed by GIs in Ambulatory Surgery Centers (ASCs) in the United States. The company provides anesthesia services in 69 GI-focused ASCs in 13 states, to approximately 450,000 patients per year, using a team of more than 700 Certified Registered Nurse Anesthetists and Physician Anesthesiologists.
History
The company was founded in 2000. It was incorporated under the name Medsurge Medical Products Corp. in 2001 pursuant to the Company Act (British Columbia). The company transitioned under the Business Corporations Act (British Columbia) in 2005 and changed its name to CRH Medical Corporation in 2006.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
